Last 33 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 116.88 | 110.13 | 59.59 | — | 55.85 | 84.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +30.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.28 | 6.28 | 6.86 | 7.23 | 7.60 | 6.31 | 5.46 | 7.48 | 5.90 | 6.46 | 9.30 | 5.55 | 5.53 | 2.15 | 28.20 | 60.49 | 76.17 | 376.22 | — | — | — |
| — | -0.5% | +25.6% | -3.4% | +28.8% | -2.3% | -41.3% | +34.8% | +6.8% | +200.3% | -67.0% | -90.8% | -92.7% | -99.4% | — | — | — | — | — | — | — | |
| P/B Ratio | 17.16 | 14.82 | 16.15 | 16.07 | 20.79 | 15.85 | 12.81 | 13.82 | 10.70 | 7.38 | 6.16 | 4.89 | 3.37 | 7.02 | 7.27 | 4.82 | 4.30 | 4.03 | 5.61 | 3.83 | 3.50 |
| — | -6.5% | +26.1% | +16.3% | +94.4% | +114.7% | +108.0% | +182.4% | +217.1% | +5.2% | -15.3% | +1.6% | -21.7% | +74.1% | +29.7% | +25.6% | +23.1% | +22.2% | +70.4% | +26.4% | -21.7% | |
| P/FCF | 53.53 | 48.09 | 71.37 | 340.31 | 37.61 | — | 1809.45 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | -96.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 84.44 | 92.46 | 53.60 | — | 51.48 | 70.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +30.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 77.33 | 54.91 | — | 46.75 | 60.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +27.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.2% | 91.3% | 91.6% | 90.7% | 91.0% | 91.2% | 90.8% | 86.6% | 90.3% | 87.7% | 88.8% | 93.4% | 83.4% | 96.9% | 85.0% | 71.8% | 83.6% | 62.9% | — | — | — |
| — | +0.1% | +0.8% | +4.8% | +0.7% | +4.0% | +2.3% | -7.3% | +8.3% | -9.5% | +4.4% | +30.0% | -0.3% | +54.1% | — | — | — | — | — | — | — | |
| Operating Margin | -3.3% | 6.6% | 12.7% | -8.6% | 14.2% | 8.6% | -17.9% | -37.3% | -10.7% | -87.3% | -162.3% | -63.8% | -452.2% | -96.8% | -1286.4% | -2742.4% | -2310.8% | -14448.0% | — | — | — |
| — | -23.7% | +170.6% | +76.9% | +232.8% | +109.8% | +89.0% | +41.6% | +97.6% | +9.9% | +87.4% | +97.7% | +80.4% | +99.3% | — | — | — | — | — | — | — | |
| Net Margin | -4.3% | 6.1% | 11.6% | -10.7% | 13.4% | 7.5% | -19.5% | -38.1% | -15.1% | -92.8% | -169.6% | -71.4% | -490.0% | -117.5% | -1367.8% | -2867.2% | -2432.3% | -14856.4% | — | — | — |
| — | -18.1% | +159.3% | +71.8% | +188.9% | +108.0% | +88.5% | +46.7% | +96.9% | +21.0% | +87.6% | +97.5% | +79.9% | +99.2% | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.3% | 3.8% | 7.3% | -6.0% | 10.0% | 5.0% | -11.3% | -16.7% | -6.9% | -24.2% | -25.4% | -22.6% | -97.9% | -70.4% | -64.5% | -45.7% | -30.0% | -46.2% | -30.0% | -23.3% | -21.6% |
| — | -24.1% | +164.9% | +64.3% | +245.8% | +120.6% | +55.7% | +26.0% | +93.0% | +65.6% | +60.5% | +50.6% | -226.6% | -52.3% | -114.8% | -95.7% | -38.9% | -215.3% | -209.2% | -133.5% | -40.7% | |
| ROA | -4.1% | 1.7% | 3.2% | -2.5% | 4.3% | 2.0% | -4.6% | -7.2% | -2.7% | -9.4% | -11.3% | -8.6% | -20.9% | -14.6% | -20.3% | -19.2% | -15.0% | -26.6% | -20.3% | -16.7% | -17.9% |
| — | -15.2% | +169.4% | +65.0% | +257.7% | +121.8% | +59.8% | +16.2% | +86.9% | +35.5% | +44.1% | +55.1% | -39.0% | +45.2% | +0.0% | -15.5% | +16.2% | -91.5% | -118.3% | -77.9% | -30.7% | |
| ROIC | -5.2% | 2.3% | 4.3% | -3.2% | 7.3% | 3.2% | -5.8% | -9.3% | -2.7% | -10.9% | -13.7% | -10.6% | -26.2% | -17.1% | -22.7% | -18.4% | -13.7% | -26.1% | -20.9% | -17.5% | -18.1% |
| — | -29.1% | +174.2% | +65.2% | +372.3% | +129.4% | +57.4% | +12.7% | +89.8% | +36.4% | +39.8% | +42.5% | -91.1% | +34.4% | -8.6% | -5.6% | +24.2% | -96.0% | -64.3% | -21.9% | -20.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.47 | 0.52 | 0.60 | 0.03 | 0.72 | 0.79 | 0.78 | 0.70 | 1.33 | 1.11 | 0.92 | 2.32 | 4.39 | 2.54 | 1.46 | 0.97 | 0.74 | 0.40 | 0.31 | 0.26 |
| — | -34.7% | -34.7% | -22.1% | -95.3% | -45.8% | -28.8% | -15.5% | -69.8% | -69.7% | -56.1% | -36.9% | +140.3% | +489.4% | +534.0% | +374.4% | +270.9% | +5069.5% | +3127.6% | +2640.2% | +1320.4% | |
| Debt / EBITDA | — | 11.46 | 6.72 | — | 0.33 | 12.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -8.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.17 | 2.92 | 2.92 | 2.68 | 3.17 | 3.50 | 3.20 | 3.55 | 4.15 | 2.46 | 8.46 | 9.89 | 7.08 | 6.72 | 8.43 | 9.93 | 11.57 | 13.39 | 10.75 | 10.89 | 12.09 |
| — | -16.5% | -8.9% | -24.4% | -23.6% | +42.4% | -62.2% | -64.1% | -41.5% | -63.4% | +0.4% | -0.4% | -38.8% | -49.8% | -21.6% | -8.8% | -4.3% | -33.2% | -66.4% | -64.2% | -6.7% | |
| Quick Ratio | 2.99 | 2.66 | 2.67 | 2.46 | 2.99 | 3.28 | 3.04 | 3.37 | 3.97 | 2.38 | 8.19 | 9.61 | 6.80 | 6.39 | 8.14 | 9.70 | 11.37 | 13.27 | 10.75 | 10.89 | 12.09 |
| — | -18.9% | -12.2% | -27.1% | -24.5% | +37.9% | -62.8% | -65.0% | -41.7% | -62.8% | +0.7% | -0.9% | -40.2% | -51.9% | -24.3% | -10.9% | -5.9% | -33.7% | -66.4% | -64.1% | -6.7% | |
| Interest Coverage | -0.24 | 4.04 | 4.87 | -1.56 | 6.95 | 3.44 | -4.13 | -7.31 | -0.89 | -5.24 | -5.99 | -3.69 | -7.54 | -4.52 | -8.66 | -10.37 | -9.41 | -20.99 | -32.70 | -34.00 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARQT stock.
Arcutis Biotherapeutics, Inc.'s current P/E is 116.9x. The average P/E over the last 3 quarters is 75.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcutis Biotherapeutics, Inc.'s current operating margin is -3.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcutis Biotherapeutics, Inc.'s business trajectory between earnings reports.